Galcanezumab Brand Name– Emgality
What is Galcanezumab
Galcanezumab is an injectable calcitonin gene-related peptide (CGRP) antagonist indicated for migraine prophylaxis and treatment of episodic cluster headache in adults.
In clinical trials of patients with episodic migraine, monthly migraine days were significantly reduced from baseline by 4.3 to 4.7 days at 6 months in galcanezumab-treated patients in comparison to 2.3 to 2.8 days for placebo. At month 3, galcanezumab-treated chronic migraine patients experienced a significant 4.8-day reduction from baseline in monthly migraine days vs. placebo.
A 50% or greater reduction in monthly migraine days was achieved by 59% to 62% of episodic migraineurs and 28% of chronic migraineurs who were treated with galcanezumab compared to 36% to 39% of episodic migraineurs and 15% of chronic migraineurs given placebo.
Cluster headache attack frequency was significantly reduced from baseline by 8.7 days at week 3 in galcanezumab-treated patients in comparison to 5.2 days for placebo.
A reduction from baseline of 50% or more in weekly cluster headache attack frequency was achieved by 71.4% of galcanezumab-treated patients compared to 52.6% for placebo.
- cluster headache
- migraine prophylaxis
- anaphylactoid reactions
- antibody formation
- injection site reaction
- laboratory monitoring not necessary
There are no drug interactions associated with Galcanezumab products.